Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (10435)	6/14/1999 3:23:00 PM
From: Edward Paule	Read Replies (1) \| Respond to of 17367

>>>>> Hope that helps. <<<<< No. >>>>> xoma.com <<<<< I've read this before, and I just reread it again. >>>>> The answer lies in lbp IMO. Xoma is not targeting gram negs but instead high lbp conditions. Lbp is abnormally high in many disease states. Lbp attached to cd14 and kicks off the inflamatory cascade []. Soooooooooooo, if lbp is the trigger and bpi21 takes the available cd14 sites away from lbp then NO kick-off. How simple. <<<<< How does the above link support this? My understanding is that neither LBP or rBPI21 or LPS attach to CD14. My understanding is that LBP bound to LPS (LBP/LPS) attaches to CD14 and that rBPI21 bound to LPS (rBPI21/LPS) doesn't. Thuuuuuuuuuus, bBPI21 binding to LPS reduces to amount of LPS available to bind with LBP, thereby reducing the amount of LBP/LPS that can attach to CD14.